코아스템켐온
Financials
Valuation Metrics
코아스템켐온's Market Cap is ₩1108B. At end of 2025 it was ₩977B. Ranked #1220 of 2,421 in KR market (top 50%), #657 of 1,640 on KOSDAQ (top 40%), #138 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 60%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 110.76B KRW | KR#1,220/2,421 Sec#138/231 |
| Revenue | 18.29B KRW | KR#2,164/2,421 Sec#159/231 |
| Net Income | -27.81B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 104.01B KRW | KR#1,742/2,421 Sec#138/231 |
| Net Assets | 44.40B KRW | KR#1,988/2,421 Sec#171/231 |
| Employees | 376 | KR#647/2,421 Sec#56/231 |
| Value | ||
| P/B | 2.49x | KR#2,040/2,421 Sec#158/231 |
| P/S | 6.06x | KR#2,191/2,421 Sec#147/231 |
| FCF Yield | -14.37% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -62.63% | KR#2,302/2,421 Sec#204/231 |
| ROA | -26.74% | KR#2,294/2,421 Sec#193/231 |
| Op. Margin | -113.93% | KR#2,314/2,421 Sec#178/231 |
| Revenue Growth | -26.34% | KR#2,191/2,421 Sec#195/231 |
| Financial Health | ||
| Debt Ratio | 134.26% | KR#1,827/2,421 Sec#203/231 |
| Total Debt | 36.71B KRW | KR#1,134/2,421 Sec#80/231 |
| FCF | -15.92B KRW | KR#1,835/2,421 Sec#171/231 |
| Cash | 4.44B KRW | KR#2,050/2,421 Sec#191/231 |
| Current Ratio | 0.27x | KR#2,215/2,421 Sec#216/231 |
| Performance | ||
| 1Y Return | 3.97% | KR#658/2,421 Sec#41/231 |
| 1M Return | 6.89% | KR#636/2,421 Sec#45/231 |
| From 52W High | -65.66% | KR#2,056/2,421 Sec#171/231 |
| 1Y MDD | -65.79% | KR#1,787/2,421 Sec#148/231 |
| Trading | ||
| Volume | 79,870 shares | KR#892/2,421 Sec#91/231 |
| Trading Value | 166.5M KRW | KR#1,341/2,421 Sec#136/231 |
| Foreign Own. | 1.22% | KR#1,940/2,421 Sec#189/231 |
| Per Share | ||
| EPS | -526 KRW | KR—/2,421 Sec—/231 |
| BPS | 840 KRW | KR#2,334/2,421 Sec#217/231 |
Company Info
Established in 2003 and listed on KOSDAQ in 2015, Corestem ChemOn merged with Kellun Co., Ltd., a top-three domestic non-clinical Contract Research Organization, in 2022. The company specializes in the production and sale of treatments for rare and intractable diseases based on stem cell technology, successfully commercializing stem cell therapies since 2015. It collaborates with clinical centers to develop and rapidly commercialize cell therapies, aiming to become a global leader through overseas license-out agreements and expanded indications. Corestem ChemOn is headquartered in Seongnam-si, Gyeonggi-do.